Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors
- 25 June 2002
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 34 (4) , 428-436
Abstract
Gain of chromosome arm 17q is a powerful prognostic factor in neuroblastoma, and the distribution of 17q breakpoints suggests that the dosage of one or more genes in 17q22–23 to 17qter is critical for tumor progression. To identify the smallest region of 17q gain, we used eight probes to map translocation breakpoints in 48 primary neuroblastoma tumors. We identified at least five different breakpoints, all localized within the proximal part of 17q (from D17Z1 to MPO). The shortest region of gain identified by these probes extends from MPO (17q23.1) to 17qter. Surprisingly, we found that breakpoints localized proximal to ERBB2 (17q12) were associated with significantly better patient survival than breakpoints localized distal to ERBB2. Breakpoints localized distal to ERBB2 identified patients with a particularly poor prognosis, higher mitotic karyorrhectic index, and stage 4 disease. This implies that breakpoint position on 17q is a discriminative factor within this prognostically poor group of patients. This result also suggests that the biological effect of 17q gain during neuroblastoma progression has a complex basis. We propose that this involves dosage alterations of genes localized on both sides of the 17q breakpoints, with a gene or genes mapping between 17cen and 17q12 acting to suppress progression, and a gene or genes mapping between 17q23.1 and 17qter acting to promote tumor progression.Keywords
Funding Information
- The North of England Children's Cancer Research Fund
This publication has 31 references indexed in Scilit:
- Online Access to CGH Data of DNA Sequence Copy Number ChangesThe American Journal of Pathology, 2000
- Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group ‘Survey’ 1982–1992European Journal of Cancer, 2000
- DNA sequence copy number increase at 8q: A potential new prognostic marker in high-grade osteosarcomaInternational Journal of Cancer, 1999
- Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell linesGenes, Chromosomes and Cancer, 1998
- Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patientsEuropean Journal of Cancer, 1997
- COMPARATIVE GENOMIC HYBRIDIZATION (CGH) ANALYSIS OF NEUROBLASTOMAS—AN IMPORTANT METHODOLOGICAL APPROACH IN PAEDIATRIC TUMOUR PATHOLOGYThe Journal of Pathology, 1997
- Molecular cytogenetic analysis of 1;17 translocations in neuroblastomaEuropean Journal of Cancer, 1995
- Cytogenetic abnormalities of small round cell tumoursMedical and Pediatric Oncology, 1994
- Cellular DNA Content as a Predictor of Response to Chemotherapy in Infants with Unresectable NeuroblastomaNew England Journal of Medicine, 1984
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958